Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage I Pancreatic Cancer Clear all
Completed Phase 1Phase 2 Interventional Results available

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

NCT00201838
View directory record Official record
Conditions
Pancreatic Neoplasms, Adenocarcinoma
Interventions
Gemcitabine, Etanercept
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

NCT03147768
View directory record Official record
Conditions
Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst, Pancreatic Neuroendocrine Tumor, Pancreas; Insulinoma, Pancreatic Cyst, Pancreatic Teratoma, Pancreatic Polypeptide Tumor, Pancreatic Vipoma, Pancreatic Cystadenoma, Pancreas Injury, Pancreatic Gastrinoma, Pancreatic Glucagonoma
Interventions
Distal Pancreatectomy Sealing Using LTW
Device
Lead sponsor
Laser Tissue Welding, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

NCT00739609
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Solid Tumors
Interventions
1-methyl-D-tryptophan
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 15, 2026, 4:56 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

NCT05055323
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Pyrvinium Pamoate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Not listed Not applicable Interventional

Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer

NCT05227898
View directory record Official record
Conditions
Cancer
Interventions
Device: Attune™, Device: Cerena™
Device
Lead sponsor
Blue Note Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 15, 2026, 4:56 PM EDT
Withdrawn Phase 1 Interventional

Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

NCT02581501
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GAX - Gemcitabine, Abraxane and Xeloda
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional

Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer

NCT00003085
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
laparoscopy, ultrasound imaging
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

NCT00529984
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer
Interventions
AVX701
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Oct 15, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01585805
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Withdrawn Phase 1 Interventional

Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma

NCT06017323
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, Nab paclitaxel, Proglumide Dose level 1, Proglumide Dose level 2
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 15, 2026, 4:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03190941
View directory record Official record
Conditions
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT00576680
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor
Interventions
RAD001, Temozolomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 15, 2026, 4:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT06710756
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions
[203Pb]Pb-PSV359, [212Pb]Pb-PSV359
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Cancer in the Abdomen

NCT00003046
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT01233505
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
veliparib, capecitabine, oxaliplatin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Results available

Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer

NCT00761345
View directory record Official record
Conditions
Pancreatic Carcinoma Non-resectable, Metastatic Pancreatic Cancer
Interventions
gemcitabine, Erlotinib, low dose fractionated radiotherapy
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

NCT00783172
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Opioid Growth Factor (OGF)
Drug · Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Allentown, Pennsylvania • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

NCT04319757
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Interventions
ACE1702, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 15, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 15, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

NCT00597129
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
90Y-hPAM4
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Goshen, Indiana • Omaha, Nebraska • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 15, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
446
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 15, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

NCT04940286
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Durvalumab, Gemcitabine, Nab-paclitaxel, Oleclumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 4:56 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

NCT01882946
View directory record Official record
Conditions
Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Melanoma
Interventions
DCVax-Direct
Biological
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 15, 2026, 4:56 PM EDT